Synexus and Radiant Research Announce Merger
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees.
Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees. The enlarged entity will retain the Synexus name.
“We are delighted to be working together with the Radiant team,” said Christophe Berthoux, who has been chief executive officer for Synexus since 2010 and will lead the new company. “Best practices from Synexus, Radiant and our earlier acquisition of Research Across America will be incorporated across our global network of sites.”
Mike Clay will lead the U.S. operations of the combined business, reporting directly to Berthoux.
The new business will span 11 countries, offering access to more than 100 million patients in clinical development markets, and it will provide data-driven site selection and activation, combined with proven patient engagement and retention expertise across the U.S., Europe and Africa, according to Synexus.
Philip Ward is the European Editor for Applied Clinical Trials
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FSP Outsourcing in Clinical Research: Trends and Opportunities
June 9th 2025When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
